Table 3. Cox Hazard Regression Analysis of the Associations of Clinicopathologic Factors and MMP9 expression for Survival (n = 78).
| Univariate Cox Regression | Multivariate Cox Regression | |||||
|---|---|---|---|---|---|---|
| Variable | HR | 95%CI | p value | HR | 95%CI | p value |
| Overall survival | ||||||
| Gender | 0.986 | 0.593–1.640 | 0.957 | |||
| Age at diagnosis | 1.033 | 1.011–1.056 | 0.004 | 1.011 | 0.985–1.038 | 0.404 |
| MMP9 mRNA expression | 1.248 | 1.111–1.403 | <0.0001 | 1.171 | 1.018–1.346 | 0.027 |
| Preoperative KPS score | 0.975 | 0.955–0.995 | 0.015 | 0.969 | 0.948–0.991 | 0.006 |
| TMZ chemotherapy | 2.626 | 1.567–4.401 | <0.0001 | 2.537 | 1.407–4.575 | 0.002 |
| MGMT promoter methylation | 1.726 | 0.999–2.979 | 0.05 | 1.554 | 0.861–2.802 | 0.143 |
| IDH1 Mutation status | 2.027 | 0.956–4.295 | 0.065 | 1.396 | 0.590–3.302 | 0.448 |
| Extent of surgery | 1.443 | 0.846–2.462 | 0.178 | |||
| Progression free survival | ||||||
| Gender | 0.834 | 0.506–1.377 | 0.478 | |||
| Age at diagnosis | 1.023 | 1.002–1.044 | 0.029 | 1.004 | 0.981–1.028 | 0.71 |
| MMP9 mRNA expression | 1.2 | 1.072–1.343 | 0.002 | 1.146 | 1.012–1.299 | 0.032 |
| Preoperative KPS score | 0.983 | 0.964–1.003 | 0.092 | |||
| TMZ chemotherapy | 2.628 | 1.579–4.375 | <0.0001 | 2.2 | 1.280–3.781 | 0.004 |
| MGMT promoter methylation | 1.671 | 0.986–2.832 | 0.057 | |||
| IDH1 Mutation status | 1.688 | 0.829–3.440 | 0.149 | |||
| Extent of surgery | 1.544 | 0.914–2.608 | 0.105 | |||
Abbreviations: KPS, Karnofsky performance status; TMZ: temozolomide; MGMT: O6-methylguanine-DNA methyltransferase; IDH1: isocitrate dehydrogenase 1; HR: hazard ratio.